Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Aim. The aim of this study is determination of the role of certain pro-inflammatory and anti-inflammatory cytokines in the pathogenesis of psoriasis. Material and methods. The 110 patients with plaque form of psoriasis of moderate severity were examined, who were divided into 2 groups. Group 1 includes 65 patients (43 men and 22 women) from 18 to 64 years old with a duration of disease from 1 year to 39 years. The traditional treatment (detoxification, antioxidant, antihistamine, multivitamin, membrane stabilizing, local anti-inflammatory) was prescribed to the patients of group 1. Group 2 includes 45 patients from 18 to 65 years old (31 men and 14 women) with a duration of disease from 6 months to 32 years. The alternative treatment (with traditional therapy, the hepatoprotectors was also used) was prescribed to the patients of group 2. The control group makes 18 practically healthy periodic donors (9 men and 9 women) from 19 to 57 years old. The level of IFNγ, TNFα, IL-1α, IL-2, IL-10 and TGFβ was investigated in the serum of psoriatic patients by ELISA (commercial kits of Demeditec Diagnostics GmbH were used). Results. Before the treatment, the significant increase of level of circulating pro-inflammatory cytokines and significant decrease of level of anti-inflammatory cytokines were seen in both groups of patients with psoriasis compared with the control group. After the treatment, the level of proinflammatory cytokines is significantly reduced and the level of anti-inflammatory cytokines is significantly increased in group 1, approaching to the normal values. In group 2, the level of proinflammatory cytokines decreases more than in group 1 after the treatment. The level of anti-inflammatory cytokines also increases more than in group 1 (high treatment efficiency). The intensity of the rate of decrease of PASI after treatment in patients of group 2 is at least 1.2 times higher than in I group, of DLQI after treatment in patients of group 2 is at least 1.44 times higher than in group 1. Conclusions. The registered changes in the serum of patients with moderate severity of papular-plaque form of psoriasis indicate their essential role in the pathogenesis of psoriasis.

Full Text

Restricted Access

About the authors

Sh. V Karapetyan

Erevan State Medical University n.a. M. Heratsi

Yerevan, 0025, Republic of Armenia

Khachik M. Khachikyan

Erevan State Medical University n.a. M. Heratsi

MD, PhD, DSc., head of department of dermatovenereology and cosmetology Erevan State Medical University n.a. M. Heratsi, Yerevan, 0025, Republic of Armenia Yerevan, 0025, Republic of Armenia


  1. Puig L., Julia A., Marsal S. The pathogenesis and genetics of psoriasis. Aclas Dermosifiliogr. 2014; 105(6): 535-45.
  2. Mahil S.K., Capon F., Barker J.N. Genetics of psoriasis. Dermatol. Clin. 2015; 33(1): 1-11.
  3. Lowes M.A., Lew W., Krueger J.G. Current concepts in the immunopathogenesis of psoriasis. Dermatol. Clin. 2004; 22(4): 349-69.
  4. Gudjonsson J.E., Johnston A., Sigmundsdottir H., Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin. Exp. Immunol. 2004; 135(1): 1-8.
  5. Kim J., Krueger J.G. The immunopathogenesis of psoriasis. Dermatol. Clin. 2015; 33(1): 13-23.
  6. Global report on psoriasis. Accessed at:
  7. Weigle N., McBane S. Psoriasis. Am. Fam. Physician. 2013; 87(9): 626-33.
  8. Kimball A.B., Jacobson C., Weiss S., Vreeland M.G., Wu Y. The psychosocial burden of psoriasis. Am. J. Clin. Dermatol. 2005; 6(6): 383-92.
  9. Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 2001; 137(3): 280-84.
  10. Weiss S.C., Kimball A.B., Liewehr D.J., Blauvelt A., Turner M.L., Emanuel E.J. Quantifying the harmful effect of psoriasis on health-related quality of life. J. Am. Acad. Dermatol. 2002; 47(4): 512-18.
  11. Akay A., Pekcanlar A., Bozdag K.E., Altintas L., Karaman A. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J. Am. Acad. Dermatol. 2002; 16(4): 347-52.
  12. Fortes C., Mastroeni S., Leffondre K., Sampogna F., Melchi F., Mazzotti E., et al. Relationship between smoking and the clinical severity of psoriasis. Arch. Dermatol. 2005; 141(12): 1580-84.
  13. Fortune D.G., Main C.J., O’Sullivan T.M., Griffiths C.E. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br. J. Dermatol. 1997; 137(5): 755-60.
  14. Kimball A.B., Leonardi C., Stahle M., Gulliver W., Chevrier M., Fakharzadeh S., et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, diseasebased registry (PSOLAR). Br. J. Dermatol. 2014; 171(1): 137-47.
  15. Gelfand J.M., Troxel A.B., Lewis J.D., Kurd S.K., Shin D.B., Wang X., et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch. Dermatol. 2007; 143(12): 1493-99.
  16. Arican O., Aral M., Sasmaz S., Ciragil P. Serum levels of TNFα, IFNγ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005; 2005(5): 273-9.
  17. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature. 2007; 445(7130): 866-73.
  18. Fuentes-Duculan J., Suarez-Farinas M., Zaba L.C., Nograles K.E., Pierson K.C., Mitsui H., et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J. Invest. Dermatol. 2010; 130(10): 2412-22.
  19. Nestle F., Kaplan D.H., Barker J.H. Psoriasis. N. Engl. J. Med. 2009; 361(5): 496-509.
  20. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J. Eur. Acad. Dermatol. Venereol. 2012; 26(Suppl. 2): 3-11.
  21. Jadali Z., Izad M., Eslami M.B., Mansouri P., Safari R., Bayatian P., et al. Th1/Th2 cytokines in psoriasis. Iran J. Publ. Health. 2007; 36(2): 87-91.
  22. Szegedi A., Aleksza M., Gonda A., Irinyi B., Sipka S., Hunyadi J., Antal-Szalmás P. Elevated rate of T-helper-1 lymphocytes and serum IFN-gamma levels in psoriatic patients. Immunol. Lett. 2003; 86(3): 277-80.
  23. Coondoo A. The role of cytokines in the pathomechanism of cutaneous disorders. Indian J. Dermatol. 2012; 57(2): 90-6.
  24. Furue M., Cadone T. “Inflammatory skin march” in atopic dermatitis and psoriasis. Inflamm. Res. 2017; 66(10): 833-42. doi: 10.1007/s00011-017-1065-z.
  25. Курников Г.Ю., Шебашова Н.В., Копытова Т.В., Абалихина Е.П. Гепатотропные препараты в комплексном лечении больных псориазом. Экспериментальная и клиническая дерматокосметология. 2004; (3): 33-6.
  26. Арчаков А.И., Сельцовский Ф.П., Лисов В.И., Цыганов Д.И., Княжев В.А., Ипатова О.М., Торховская Т.И. Фосфоглив: механизм действия и эффективность применения в клинике. Вопросы медицинской химии. 2002; 48(2): 139-53.
  27. Menter A., Smith C., Barker J. Psoriasis. Oxford: Health Press; 2004.
  28. Augustin M., Krüger K., Radtke M.A., Schwipp I., Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008; 216(4): 366-72.
  29. Кубанов А.А., Карамова А.Э., Знаменская Л.Ф., Чикин В.В., Кондрашова В.В. Индекс PASI (Psoriasis Area and Severity Index) в оценке клинических проявлений псориаза. Вестник дерматологии и венерологии. 2016; (4): 33-8.
  30. Адаскевич В.П. Диагностические индексы в дерматологии. М.: Издательство Панфилова; БИНОМ; 2014.
  31. Mattei P.L., Corey K.C., Kimball A.B. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J. Eur. Acad. Dermatol. Venereol. 2014; 28(3): 333-7.
  32. Hagg D., Sundstrom A., Eriksson M., Schmitt-Egenolf M. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). J. Eur. Acad. Dermatol. Venereol. 2015; 29(3): 452-6.
  33. Twiss J., Meads D.M., Preston E.P., Crawford S.R., McKenna S.P. Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? J. Invest. Dermatol. 2012; 132(1): 76-84.
  34. Vender R., Lynde C., Gilbert M., Ho V., Sapra S., Poulin-Costello M. Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice. J. Cutan. Med. Surg. 2012; 16(6): 407-16.



Abstract: 124


Article Metrics

Metrics Loading ...


Copyright (c) 2018 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies